A Randomized, Double-blind, Placebo-controlled Dose-ranging Study of OPK-88004 Once-a-day Dosing for 16 Weeks in Men With Signs and Symptoms of Benign Prostatic Hyperplasia. NCT03297398, SAR-202

    Not Recruiting
Updated on 29 September 2022


This study will evaluate the safety and effectiveness of different doses of OPK-88004 compared to placebo on prostate size and related lower urinary tract symptoms (LUTS) in men with benign prostatic hyperplasia (BPH).


For more information contact Cheryl Zinar, Director of Clinical Research, Urologic Consultants of Southeastern PA.

Condition Benign Prostatic Hyperplasia (Enlarged Prostate)
Clinical Study IdentifierTX196750
Last Modified on29 September 2022

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note